Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.54
BMY's Cash to Debt is ranked higher than
53% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. BMY: 0.54 )
BMY' s 10-Year Cash to Debt Range
Min: 0.36   Max: 2.26
Current: 0.54

0.36
2.26
Equity to Asset 0.39
BMY's Equity to Asset is ranked lower than
51% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. BMY: 0.39 )
BMY' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.52
Current: 0.39

0.33
0.52
Interest Coverage 15.56
BMY's Interest Coverage is ranked higher than
57% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 90.51 vs. BMY: 15.56 )
BMY' s 10-Year Interest Coverage Range
Min: 4.67   Max: 50.72
Current: 15.56

4.67
50.72
F-Score: 5
Z-Score: 4.11
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 18.90
BMY's Operating margin (%) is ranked higher than
88% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. BMY: 18.90 )
BMY' s 10-Year Operating margin (%) Range
Min: 10.45   Max: 31.29
Current: 18.9

10.45
31.29
Net-margin (%) 15.64
BMY's Net-margin (%) is ranked higher than
88% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. BMY: 15.64 )
BMY' s 10-Year Net-margin (%) Range
Min: 9.19   Max: 56.42
Current: 15.64

9.19
56.42
ROE (%) 16.91
BMY's ROE (%) is ranked higher than
93% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. BMY: 16.91 )
BMY' s 10-Year ROE (%) Range
Min: 14.39   Max: 71.49
Current: 16.91

14.39
71.49
ROA (%) 6.64
BMY's ROA (%) is ranked higher than
81% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. BMY: 6.64 )
BMY' s 10-Year ROA (%) Range
Min: 5.46   Max: 34.22
Current: 6.64

5.46
34.22
ROC (Joel Greenblatt) (%) 44.94
BMY's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. BMY: 44.94 )
BMY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 38.47   Max: 147.02
Current: 44.94

38.47
147.02
Revenue Growth (%) -4.40
BMY's Revenue Growth (%) is ranked higher than
54% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. BMY: -4.40 )
BMY' s 10-Year Revenue Growth (%) Range
Min: -4.4   Max: 11.8
Current: -4.4

-4.4
11.8
EBITDA Growth (%) -16.30
BMY's EBITDA Growth (%) is ranked higher than
53% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. BMY: -16.30 )
BMY' s 10-Year EBITDA Growth (%) Range
Min: -16.7   Max: 21.5
Current: -16.3

-16.7
21.5
EPS Growth (%) -5.10
BMY's EPS Growth (%) is ranked higher than
66% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. BMY: -5.10 )
BMY' s 10-Year EPS Growth (%) Range
Min: -22.9   Max: 30.7
Current: -5.1

-22.9
30.7
» BMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

BMY Guru Trades in Q2 2013

George Soros 100,000 sh (New)
Steven Cohen 495,022 sh (+4489.06%)
Jean-Marie Eveillard 66,520 sh (+302.66%)
Jeremy Grantham 7,577,933 sh (+22.26%)
Vanguard Health Care Fund 20,338,461 sh (+13.32%)
Manning & Napier Advisors, Inc 264,730 sh (+7.02%)
Ken Fisher 14,503 sh (+6.13%)
Dodge & Cox 80,121 sh (unchged)
Brian Rogers 5,864,800 sh (unchged)
Ray Dalio Sold Out
Prem Watsa Sold Out
Bill Frels 327,256 sh (-0.32%)
Murray Stahl 61,410 sh (-0.97%)
Pioneer Investments 86,123 sh (-2.5%)
Jeff Auxier 5,782 sh (-14.11%)
Mario Gabelli 804,625 sh (-15.48%)
Jim Simons 8,530,800 sh (-39.57%)
Irving Kahn 55,433 sh (-86.62%)
» More
Q3 2013

BMY Guru Trades in Q3 2013

Paul Tudor Jones 225,000 sh (New)
Steven Cohen 1,841,982 sh (+272.1%)
Vanguard Health Care Fund 24,459,861 sh (+20.26%)
Jeremy Grantham 8,368,932 sh (+10.44%)
Ken Fisher 15,937 sh (+9.89%)
Manning & Napier Advisors, Inc 266,455 sh (+0.65%)
Jeff Auxier 5,782 sh (unchged)
Dodge & Cox 80,121 sh (unchged)
Brian Rogers 5,864,800 sh (unchged)
George Soros 100,000 sh (unchged)
Pioneer Investments 85,502 sh (-0.72%)
Murray Stahl 60,572 sh (-1.36%)
Mario Gabelli 769,900 sh (-4.32%)
Bill Frels 304,956 sh (-6.81%)
Irving Kahn 28,300 sh (-48.95%)
Jim Simons 4,338,900 sh (-49.14%)
Jean-Marie Eveillard 16,520 sh (-75.17%)
» More
Q4 2013

BMY Guru Trades in Q4 2013

Stanley Druckenmiller 954,200 sh (New)
Joel Greenblatt 11,679 sh (New)
Ken Fisher 18,138 sh (+13.81%)
Jeremy Grantham 8,939,857 sh (+6.82%)
Murray Stahl 62,672 sh (+3.47%)
Pioneer Investments 86,808 sh (+1.53%)
Vanguard Health Care Fund 24,459,861 sh (unchged)
Brian Rogers 5,864,800 sh (unchged)
Jeff Auxier 5,782 sh (unchged)
George Soros 100,000 sh (unchged)
Jean-Marie Eveillard 16,520 sh (unchged)
Dodge & Cox 79,921 sh (-0.25%)
Bill Frels 300,756 sh (-1.38%)
Irving Kahn 27,650 sh (-2.3%)
Mario Gabelli 730,771 sh (-5.08%)
Manning & Napier Advisors, Inc 241,961 sh (-9.19%)
Paul Tudor Jones 100,000 sh (-55.56%)
Steven Cohen 630,599 sh (-65.77%)
Jim Simons 41,200 sh (-99.05%)
» More
Q1 2014

BMY Guru Trades in Q1 2014

Brian Rogers 5,864,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 New Buy0.02%$46.41 - $53.84 $ 49.46-3%11679
Vanguard Health Care Fund 2013-09-30 Add 20.26%0.64%$41.32 - $47.53 $ 49.4613%24459861
Jean-Marie Eveillard 2013-09-30 Reduce -75.17%0.01%$41.32 - $47.53 $ 49.4613%16520
Vanguard Health Care Fund 2013-06-30 Add 13.32%0.39%$39.68 - $47.68 $ 49.4614%20338461
Ray Dalio 2013-06-30 Sold Out 0.07%$39.68 - $47.68 $ 49.4614%0
George Soros 2013-06-30 New Buy0.05%$39.68 - $47.68 $ 49.4614%100000
Prem Watsa 2013-06-30 Sold Out 0.01%$39.68 - $47.68 $ 49.4614%0
Jean-Marie Eveillard 2013-06-30 Add 302.66%0.01%$39.68 - $47.68 $ 49.4614%66520
Vanguard Health Care Fund 2013-03-31 Add 49.53%0.96%$32.59 - $41.19 $ 49.4635%17948561
John Hussman 2013-03-31 Sold Out 0.64%$32.59 - $41.19 $ 49.4635%0
Ray Dalio 2013-03-31 Add 267.87%0.05%$32.59 - $41.19 $ 49.4635%181140
James Barrow 2013-03-31 Sold Out 0.05%$32.59 - $41.19 $ 49.4635%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP901.560.22$2.00 Convertible Preferred Stock

Top Ranked Articles about Bristol-Myers Squibb Company

Kahn Brothers Reduce BMY, SLM, TRV, USG, PFE, LARK in Second Quarter
Thomas Kahn once explained The Kahn Brothers’ investment approach: “We study companies and try to find undervalued securities... We're absolute value investors focusing on asset values, book value discounts and low price to earnings ratios to normalized earnings. And we aren't interested in so-called relative values -- you know, something selling at 20 times earnings in an industry group with a 35 multiple.” Read more...
Renaissance Man Jim Simons - A Tale of Three Pharmaceuticals and Remarkable Gains
In 1982 Guru Jim Simons founded Renaissance Technologies, an investment management company known for hiring mathematicians and physicists and adhering to mathematical and statistical methods to produce superior returns. One of the world's most successful hedge funds, the private investment firm has over $20 billion under management. The Renaissance Technologies portfolio currently lists 2,848 stocks, 750 of them new, a quarter-over-quarter turnover of 42%, and a total value of $41.2 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 32.10
BMY's P/E(ttm) is ranked higher than
62% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.60 vs. BMY: 32.10 )
BMY' s 10-Year P/E(ttm) Range
Min: 4.05   Max: 58.14
Current: 32.1

4.05
58.14
P/B 5.30
BMY's P/B is ranked lower than
56% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. BMY: 5.30 )
BMY' s 10-Year P/B Range
Min: 2.46   Max: 6.11
Current: 5.3

2.46
6.11
P/S 5.02
BMY's P/S is ranked lower than
63% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. BMY: 5.02 )
BMY' s 10-Year P/S Range
Min: 1.63   Max: 5.7
Current: 5.02

1.63
5.7
PFCF 27.40
BMY's PFCF is ranked higher than
63% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.79 vs. BMY: 27.40 )
BMY' s 10-Year PFCF Range
Min: 7.44   Max: 141.78
Current: 27.4

7.44
141.78
EV-to-EBIT 30.30
BMY's EV-to-EBIT is ranked higher than
51% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. BMY: 30.30 )
BMY' s 10-Year EV-to-EBIT Range
Min: 6.4   Max: 140.2
Current: 30.3

6.4
140.2
PEG 2.00
BMY's PEG is ranked higher than
72% of the 309 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. BMY: 2.00 )
BMY' s 10-Year PEG Range
Min: 0.68   Max: 31.58
Current: 2

0.68
31.58
Shiller P/E 19.10
BMY's Shiller P/E is ranked higher than
77% of the 363 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.59 vs. BMY: 19.10 )
BMY' s 10-Year Shiller P/E Range
Min: 10.15   Max: 22.48
Current: 19.1

10.15
22.48

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.87
BMY's Dividend Yield is ranked higher than
84% of the 418 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. BMY: 2.87 )
BMY' s 10-Year Dividend Yield Range
Min: 2.51   Max: 7.07
Current: 2.87

2.51
7.07
Dividend Payout 0.91
BMY's Dividend Payout is ranked lower than
68% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. BMY: 0.91 )
BMY' s 10-Year Dividend Payout Range
Min: 0.23   Max: 1.38
Current: 0.91

0.23
1.38
Dividend growth (3y) 3.00
BMY's Dividend growth (3y) is ranked higher than
77% of the 235 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. BMY: 3.00 )
BMY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 11.4
Current: 3

0
11.4
Yield on cost (5-Year) 3.38
BMY's Yield on cost (5-Year) is ranked higher than
80% of the 429 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. BMY: 3.38 )
BMY' s 10-Year Yield on cost (5-Year) Range
Min: 2.92   Max: 8.24
Current: 3.38

2.92
8.24
Share Buyback Rate 1.30
BMY's Share Buyback Rate is ranked higher than
92% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.70 vs. BMY: 1.30 )
BMY' s 10-Year Share Buyback Rate Range
Min: 5.1   Max: -0.3
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.20
BMY's Price/Tangible Book is ranked lower than
80% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. BMY: 14.20 )
BMY' s 10-Year Price/Tangible Book Range
Min: 5.88   Max: 53.3
Current: 14.2

5.88
53.3
Price/DCF (Projected) 1.60
BMY's Price/DCF (Projected) is ranked higher than
69% of the 349 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. BMY: 1.60 )
BMY' s 10-Year Price/DCF (Projected) Range
Min: 1.13   Max: 4.14
Current: 1.6

1.13
4.14
Price/Median PS Value 1.90
BMY's Price/Median PS Value is ranked lower than
65% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. BMY: 1.90 )
BMY' s 10-Year Price/Median PS Value Range
Min: 0.89   Max: 3.27
Current: 1.9

0.89
3.27
Price/Graham Number 4.50
BMY's Price/Graham Number is ranked lower than
67% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. BMY: 4.50 )
BMY' s 10-Year Price/Graham Number Range
Min: 1.66   Max: 10.79
Current: 4.5

1.66
10.79
Earnings Yield (Greenblatt) 3.30
BMY's Earnings Yield (Greenblatt) is ranked higher than
59% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. BMY: 3.30 )
BMY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 15.6
Current: 3.3

0.7
15.6
Forward Rate of Return (Yacktman) -10.68
BMY's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. BMY: -10.68 )
BMY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.5   Max: 26.8
Current: -10.68

-10.5
26.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BRM.Germany, BMYMP.USA
Bristol-Myers Squibb Co, a Delaware corporation was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: BioPharmaceuticals. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes (typically involving recombinant DNA technology), called 'biologics'. Small molecule drugs are typically administered orally, e.g., in the form of a pill or tablet, although other drug delivery mechanisms are used as well. Biologics are typically administered to patients through injections or by infusion. Its revenues come from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience and metabolics. Regional commercial organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company's key prodcts include, Plavix , Avapro , Eliquis , Reyataz , Sustiva Franchise , Baraclude , Sprycel, Yervoy, Orencia among others.The Company promotes its products directly to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The markets in which the Company competes are generally broad-based and highly competitive. The Company competes with other research-based drug companies, many smaller research companies and generic drug manufacturers. The Company is subject to global regulation by regional, country, state and local agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide